NTx-265 is a therapeutic regimen of two approved and clinically well-defined drugs, human Chorionic Gonadotropin and Erythropoietin, targeting the treatment of stroke. The objective of the regimen is to stimulate the growth and differentiation of new neurons to replace the brain cells that were lost or damaged by the stroke.

Highest Dev Status	Phase 2
Therapeutic Area	Cardiovascular
Potential Indications	Please Login
Identified Action Mechanisms	3
Literature	NCBI